ArticleFrontiers in nutrition2025
Predictive value of the serum albumin change rate for therapeutic response to targeted therapy in patients with AIDS-related non-Hodgkin lymphoma.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the predictive value of the serum albumin change rate (Alb Change Rate) for treatment efficacy in patients with AIDS-related non-Hodgkin lymphoma (AR-NHL) undergoing targeted therapy (e.g., rituximab), and to explore the clinical implications of serum albumin (Alb) dynamics during treatment. Methods: This retrospective study included 95 patients diagnosed with AR-NHL between June 2017 and June 2024. The primary endpoint was the therapeutic response after completion of four cycles of treatment regimens containing targeted agents. Patients were categorized into two groups based on treatment response: effective and ineffective. The objective was to investigate the association between the Alb Change Rate and treatment efficacy in AR-NHL patients. Logistic regression analysis was performed to assess the association between the Alb Change Rate and treatment efficacy. Multivariate analysis was used to adjust for potential confounding variables. Results: Among 95 patients with AR-NHL (mean age: 48.99 ± 12.70 years; 78.95% male). The diffuse large B-cell lymphoma (DLBCL) was the predominant subtype (85.26%). According to Ann Arbor-Cotswolds staging, 75.79% were stage III-IV. After four cycles of targeted therapy, 64 patients (67.37%) responded effectively, while 31 (32.63%) were classified as ineffective, including five deaths. The median Alb Change Rate was 3.09% (-34.71 to 78.55%), with corresponding the Hb-Shift and the CD4 Conclusion: The Alb Change Rate is a useful predictor of treatment response in AR-NHL patients receiving targeted therapy. Alb Change Rate ≥ 0 was significantly associated with better outcomes. These results highlight the value of dynamic Alb monitoring and nutritional support during treatment. Further prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.